StockNews.AI
DXR
StockNews.AI
172 days

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

1. Daxor expands into a Midwest healthcare facility with 735 beds. 2. The BVA testing improves fluid management for cardiovascular patients. 3. The ezBVA Lab delivers results within 24 hours, enhancing patient care. 4. Service is reimbursable, requiring no capital expenditure from facilities. 5. Daxor's technology is crucial for reducing costs and improving outcomes.

6m saved
Insight
Article

FAQ

Why Bullish?

Daxor's expansion into a major facility indicates strong demand and a growing market presence, similar to past expansions that positively influenced stock prices.

How important is it?

The news highlights a significant operational advancement for Daxor, which should enhance its growth trajectory and investor sentiment.

Why Long Term?

The ongoing integration and reimbursement model will likely yield sustained revenues over time, as seen with previous successful healthcare partnerships.

Related Companies

MDTBAXNOVN
Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into a leading Midwest healthcare facility. This 735-bed medical campus will integrate Daxor’s blood volume analysis (BVA) testing into its outpatient care, enhancing precision in fluid management and patient outcomes. The program specifically targets patients with heart failure, hypertension, and other cardiovascular conditions where precise fluid management is critical to care. Blood samples will be expedited to Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility featuring state-of-the-art equipment that delivers comprehensive BVA results within 24 hours. "Precise volume management is at the heart of effective cardiovascular care, and this expansion continues to widen the ezBVA footprint in the Midwest," explained Michael Feldschuh, Daxor’s CEO and President. "Our BVA diagnostic provides clinicians with 98% accurate data, enabling personalized fluid management that improves patient outcomes while reducing costs. The ezBVA Lab service offers healthcare facilities access to our BVA technology without requiring capital expenditure. This service is fully reimbursable through established CPT codes for both inpatient and outpatient settings under public and private insurance plans." About Daxor Corporation Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE. Forward-Looking Statements Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:Bret ShapiroSr. Managing Partner, CORE IR1-516-222-2560brets@coreir.com

Related News